Universitätsklinikum Frankfurt am Main (KGU)

CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome (2022) Taube F, Georgi JA, Kramer M, Stasik S, Middeke JM, Röllig C, Krug U, et al. Journal article Decision Conflicts in Clinical Care during COVID-19: A Multi-Perspective Inquiry. (2022) Haier J, Beller J, Adorjan K, Bleich S, De Greck M, Griesinger F, Heppt M, et al. Journal article Statistical biases due to anonymization evaluated in an open clinical dataset from COVID-19 patients. (2022) Koll CE, Hopff SM, Meurers T, Lee CH, Kohls M, Stellbrink C, Thibeault C, et al. Journal article AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2022. (2022) Ditsch N, Woecke A, Untch M, Jackisch C, Albert US, Banys-Paluchowski M, Bauerfeind I, et al. Journal article, Review article AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2022. (2022) Thill M, Lueftner D, Kolberg-Liedtke C, Albert US, Banys-Paluchowski M, Bauerfeind I, Blohmer JU, et al. Journal article, Review article The Prognostic Impact of PD-L2 in Papillary Renal-Cell Carcinoma. (2022) Mondorf Y, Mikuteit M, Ivanyi P, Stoehr C, Herrmann E, Polifka I, Agaimy A, et al. Journal article Intensified cytarabine dose during consolidation in adult AML patients under 65 years is not associated with survival benefit: real-world data from the German SAL-AML registry (2022) Hanoun M, Ruhnke L, Kramer M, Hanoun C, Schaefer-Eckart K, Steffen B, Sauer T, et al. Journal article DEGRO practical guideline for central nervous system radiation necrosis part 1: classification and a multistep approach for diagnosis (2022) Bernhardt D, Koenig L, Grosu AL, Wiestler B, Rieken S, Wick W, Gempt J, et al. Journal article, Review article Effect of Denosumab Added to 2 Different nab-Paclitaxel Regimens as Neoadjuvant Therapy in Patients with Primary Breast Cancer: The GeparX 2 × 2 Randomized Clinical Trial (2022) Blohmer JU, Link T, Reinisch M, Just M, Untch M, Stotzer O, Fasching P, et al. Journal article Long-term Efficacy and Safety of Up to 108 Weeks of Ixekizumab in Pediatric Patients With Moderate to Severe Plaque Psoriasis: The IXORA-PEDS Randomized Clinical Trial. (2022) Paller AS, Seyger MMB, Magarinos GA, Pinter A, Cather JC, Rodriguez-Capriles C, Zhu D, et al. Journal article